Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.
This article was originally published by Targeted Oncology®.
The FDA has granted approval to bosutinib for the treatment of pediatric patients aged 1 year or older with CP-CML that is newly diagnosed or relapsed or refractory to prior therapy.1
Results from the phase 1/2 BCHILD study (NCT04258943) support the FDA’s decision to grant approval of bosutinib for this indication. The study showed that bosutinib had preliminary efficacy in patients with CP-CML compared with other second-generation tyrosine kinase inhibitors. The agent was also well-tolerated in patients.1,2
In the newly diagnosed CP-CML population, the median duration of follow-up was 4.2 months (range, 1.1-26.3 months). Bosutinib achieved a major cytogenetic response rate (MCyR) of 76.2% (95% CI, 52.8-91.8) and complete cytogenetic response rate (CCyR) of 71.4% (95% CI, 47.8-88.7). Further, the major molecular response rate was 28.6% (95% CI, 11.3-52.3).
Among patients with relapsed/refractory CP-CML, the median duration of follow-up was 23.2 months (range, 1-61.5 months). MCyR observed with bosutinib was 82.1% (95% CI, 63.1- 93.9), and the CCyR was 78.6% (95% CI, 59-91.7). Fourteen patients from the cohort achieved a MMR, and of them 2 patients lost MMR after 13.6 and 24.7 months on treatment, respectively.
Occurring in at least 20% of patients in the study, the most common adverse events were diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, pyrexia, decreased appetite, and constipation. Further, increased creatinine, increased alanine aminotransferase or aspartate aminotransferase, decreased white blood cell count, and decreased platelet count were the most common laboratory abnormalities, which were observed in 45% of patients or more.
References
1. FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia. News release. FDA. September 27, 2023. Accessed. September 27, 2023. https://tinyurl.com/bdza5my2
2. Pennesi E, Brivio E, Willemse ME, et al. Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). J Clin Oncol. 2023;41(suppl 16): 10017. doi:10.1200/JCO.2023.41.16_suppl.10017
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More